# Clinical Investigations and Precision Therapeutics

> **NIH NIH P30** · RBHS -CANCER INSTITUTE OF NEW JERSEY · 2021 · $29,658

## Abstract

CLINICAL INVESTIGATIONS AND PRECISION THERAPEUTICS 
PROJECT SUMMARY/ABSTRACT 
The overall goals of the Clinical Investigations and Precision Therapeutics (CIPT) Program are to translate 
outstanding science into early phase trials, to develop new diagnostic, prevention, and therapeutic strategies 
for human cancer, and to promote bidirectional translation from bench to bedside and back. CIPT provides a 
translational bridge between the basic science and population science programs and the clinic, and conducts 
its own programmatically aligned translational research. CIPT is unique in its centralization of experience in 
the development of early phase clinical trials with expertise in molecular biology, genomics, imaging analysis, 
systems biology, statistics, and biomarker development. CIPT members translate scientific findings to create 
new paradigms at the bench and in the clinic, and are positioned within this multidisciplinary framework to 
access the expertise necessary for high impact translational research. High impact translational projects are 
prioritized for institutional support. CIPT has 60 members from 22 Departments and 7 Schools. CIPT 
research is well funded with $5.6M annual direct peer-reviewed grant support, $4.4M of which is cancer- 
focused (9 multi-PI), with $2.3M from the NCI (8 R01-equivalent/7 PIs, one UM1). In the last funding period 
CIPT members published 929 papers, 42% of which were collaborative (29% intra- and 25% inter- 
collaborations) with 51% collaborative with other institutions. This represents an increase in both total and 
collaborative publications compared with last project period. Impactful science includes discovery of 
compounds that reactivate specific conformational mutants of p53 in collaboration with the Cancer 
Pharmacology Program (CP); development of rational combinations of MAPK pathway and apoptosis 
inhibition, and targeting cancer metabolism by inhibiting autophagy in collaboration with the Cancer 
Metabolism and Growth Program, (CMG); and identification of mechanisms of resistance to PARP inhibitors in 
BRCA1 mutant cancers in collaboration with Genome Instability and Cancer Genetics Program (GICG). These 
approaches are being assessed in the clinic and in mouse models. CIPT investigators worked with CMG and 
GICG investigators to identify novel markers of response to immune checkpoint therapy, including presence of 
DNA polymerase-epsilon mutations in endometrial cancer. Collaboration with biomedical engineers in CP led 
to development of a classifier to help guide treatment of early stage ER+ breast cancer based on 
computational analysis of digital histology images. Collaboration with the Cancer Prevention and Control 
Program (CPC) led to studies evaluating the impact of mental illness on breast cancer outcome in the elderly. 
Finally, clinical investigation of immune checkpoint therapy in Merkel cell carcinoma led to FDA approval of 
avelumab for advanced disease. CIPT science is fue...

## Key facts

- **NIH application ID:** 10112877
- **Project number:** 5P30CA072720-22
- **Recipient organization:** RBHS -CANCER INSTITUTE OF NEW JERSEY
- **Principal Investigator:** Shridar Ganesan
- **Activity code:** P30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2021
- **Award amount:** $29,658
- **Award type:** 5
- **Project period:** 1997-03-01 → 2024-02-29

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10112877

## Citation

> US National Institutes of Health, RePORTER application 10112877, Clinical Investigations and Precision Therapeutics (5P30CA072720-22). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10112877. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*